Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Oncology News
  3. ESMO Videos

ESMO 2019 Highlights in metastatic castration resistant prostate cancer: The PROFOUND study

David Olmos reports on key results from ESMO Congress 2019 on LBA12_PR: PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Produced by the European Society for Medical Oncology https://oncologypro.esmo.org

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.